ESLO-TEL

Main information

  • Trade name:
  • ESLO-TEL 10 TAB
  • Dosage:
  • 40,5;MG(-)AMLODIPINE)
  • Pharmaceutical form:
  • TAB
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ESLO-TEL 10 TAB
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

12-11-2018

AMvB in consultatie voor inrichting wietteeltexperiment

AMvB in consultatie voor inrichting wietteeltexperiment

Minister Bruins voor Medische Zorg en minister Grapperhaus van Justitie en Veiligheid  hebben vandaag de concept algemene maatregel van bestuur (AMvB) voor de inrichting van het ‘Experiment gesloten coffeeshopketen’ in consultatie gedaan. De concept-AMvB betreft een nadere invulling van de regels, die zijn opgenomen in het wetsvoorstel experiment gesloten coffeeshopketen dat in juli 2018 aan de Tweede Kamer is aangeboden. Gedurende zes weken kan iedereen op dit concept reageren. Daarnaast schrijven minis...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

22-8-2018

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industr...

FDA - U.S. Food and Drug Administration

18-8-2018

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probabl...

FDA - U.S. Food and Drug Administration

6-7-2018

Wietexperiment meet effect op criminaliteit, veiligheid, overlast en volksgezondheid

Wietexperiment meet effect op criminaliteit, veiligheid, overlast en volksgezondheid

Het rapport van de Adviescommissie Experiment gesloten cannabisketen biedt voor het kabinet concrete handvatten voor de uitwerking van het experiment met cannabisteelt voor recreatief gebruik in de gesloten coffeeshopketen. De ministerraad heeft op voorstel van minister Bruins voor Medische Zorg en Sport en minister Grapperhaus van Justitie en Veiligheid besloten het wietteeltexperiment zodanig op te zetten dat het effect goed te meten is op criminaliteit, veiligheid, overlast en volksgezondheid.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

29-6-2018

Nieuwe behandeling tegen hepatitis C in het basispakket

Nieuwe behandeling tegen hepatitis C in het basispakket

Een nieuwe behandeling tegen chronische hepatitis C met het geneesmiddel Vosevi wordt vanaf 1 juli 2018 vergoed vanuit het basispakket. Dat heeft minister Bruno Bruins (Medische Zorg) besloten nadat hij met de fabrikant onderhandeld heeft over de prijs van het nieuwe middel. Vosevi kan worden ingezet bij alle patiënten met een chronische hepatitis C infectie. Met de opname van Vosevi zijn nu alle geneesmiddelen voor hepatitis C patiënten in Nederland beschikbaar vanuit het basispakket .

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

29-6-2018

Nationaal Sportakkoord ondertekend

Nationaal Sportakkoord ondertekend

Ruim 700 extra buurtsportcoaches, verhoging van de onbelaste vrijwilligersvergoeding van €1500 naar €1700 euro per jaar, €87 miljoen aan subsidie voor sportverenigingen die investeren in accommodaties, een nieuwe code goed sportbestuur en beweegprogramma’s voor kinderen onder de 6 jaar. Dit is slechts een greep uit het sportakkoord dat minister Bruno Bruins (Sport)heeft gesloten met de sport, gemeenten en maatschappelijke organisaties en bedrijven. Het is de eerste keer dat zoveel partijen zijn samengebr...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

22-6-2018

Ierland sluit zich aan bij Beneluxa

Ierland sluit zich aan bij Beneluxa

Ierland heeft zich als vijfde land aangesloten bij het Beneluxa initiatief voor samenwerking op geneesmiddelenbeleid. Minister Bruno Bruins (Medische Zorg) en de Ierse minister van Volksgezondheid, Simon Harris, hebben hierover vandaag een overeenkomst getekend met hun Belgische, Luxemburgse en Oostenrijkse collega’s. De ondertekening vond plaats tijdens de Europese Raad van Ministers van Volksgezondheid (EPSCO) in Luxemburg. 

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

20-6-2018

Advies experiment gesloten coffeeshopketen aangeboden aan ministers

Advies experiment gesloten coffeeshopketen aangeboden aan ministers

Het rapport van de Adviescommissie Experiment gesloten coffeeshopketen is vandaag aangeboden aan minister Grapperhaus van Justitie en Veiligheid en minister Bruins van Medische Zorg en Sport. Het advies van de commissie onder leiding van voorzitter professor André Knottnerus is van belang voor de inrichting van het experiment met cannabisteelt voor recreatief gebruik in de gesloten coffeeshopketen.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

1-4-2014

Danish Pharmacovigilance Update 27 February 2014

Danish Pharmacovigilance Update 27 February 2014

In this issue of Danish Pharmacovigilance Update: Further restrictions on the use of osteoporosis medicine strontium ranelate (Protelos®), Anticoagulant therapy to be stopped before initiating treatment with the new oral anticoagulants (NOACs).

Danish Medicines Agency

25-2-2014

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

The European Medicines Agency (EMA) recommends to restrict the use of the osteoporosis medicine strontium ranelate (Protelos®) to patients with severe osteoporosis who cannot be treated with other medicines approved for osteoporosis.

Danish Medicines Agency

14-11-2018

Desloratadine ratiopharm (ratiopharm GmbH)

Desloratadine ratiopharm (ratiopharm GmbH)

Desloratadine ratiopharm (Active substance: desloratadine) - Centralised - Yearly update - Commission Decision (2018)7603 of Wed, 14 Nov 2018

Europe -DG Health and Food Safety

25-10-2018

Micardis (Boehringer Ingelheim International GmbH)

Micardis (Boehringer Ingelheim International GmbH)

Micardis (Active substance: telmisartan) - Centralised - Yearly update - Commission Decision (2018)7136 of Thu, 25 Oct 2018

Europe -DG Health and Food Safety

14-8-2018

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting.  We look forward to continuing discussions around increasing medical device options for children today.  #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #MedicalDevice pic.twitter.com/7cXPFfvfif

FDA - U.S. Food and Drug Administration

19-7-2018

EU/3/16/1783 (Reglntel Ltd)

EU/3/16/1783 (Reglntel Ltd)

EU/3/16/1783 (Active substance: N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide) - Transfer of orphan designation - Commission Decision (2018)4810 of Thu, 19 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/138/16/T/02

Europe -DG Health and Food Safety

11-7-2018

Pylobactell (Torbet Laboratories Limited)

Pylobactell (Torbet Laboratories Limited)

Pylobactell (Active substance: 13C-urea) - Centralised - Yearly update - Commission Decision (2018)4517 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

3-7-2018

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4255 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/313/T/90

Europe -DG Health and Food Safety

3-7-2018

Azomyr (Merck Sharp and Dohme B.V.)

Azomyr (Merck Sharp and Dohme B.V.)

Azomyr (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4253 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/310/T/94

Europe -DG Health and Food Safety

29-6-2018

BROADLINE (Merial)

BROADLINE (Merial)

BROADLINE (Active substance: Fipronil/ S-methoprene/ Eprinomectin/ Praziquantel) - Centralised - Yearly update - Commission Decision (2018) 4164 of Fri, 29 Jun 2018

Europe -DG Health and Food Safety

27-6-2018

Copalia HCT (Novartis Europharm Limited)

Copalia HCT (Novartis Europharm Limited)

Copalia HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4082 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1159/T/67

Europe -DG Health and Food Safety

27-6-2018

Exforge (Novartis Europharm Limited)

Exforge (Novartis Europharm Limited)

Exforge (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4085 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/716/T/96

Europe -DG Health and Food Safety

27-6-2018

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4084 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1160/T/68

Europe -DG Health and Food Safety

19-6-2018

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Active substance: desloratadine; pseudoephedrine sulphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3930 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/772/T/37

Europe -DG Health and Food Safety

19-6-2018

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3931 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/314/T/88

Europe -DG Health and Food Safety

11-6-2018

Exforge HCT (Novartis Europharm Limited)

Exforge HCT (Novartis Europharm Limited)

Exforge HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3752 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1068/T/66

Europe -DG Health and Food Safety

11-6-2018

Dafiro (Novartis Europharm Limited)

Dafiro (Novartis Europharm Limited)

Dafiro (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3753 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/776/T/99

Europe -DG Health and Food Safety

6-6-2018

Copalia (Novartis Europharm Limited)

Copalia (Novartis Europharm Limited)

Copalia (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3695 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/774/T/97

Europe -DG Health and Food Safety

4-6-2018

Twynsta (Boehringer Ingelheim International GmbH)

Twynsta (Boehringer Ingelheim International GmbH)

Twynsta (Active substance: telmisartan / amlodipine) - Centralised - Yearly update - Commission Decision (2018)3625 of Mon, 04 Jun 2018

Europe -DG Health and Food Safety

29-5-2018

Profender (Bayer Animal Health GmbH)

Profender (Bayer Animal Health GmbH)

Profender (Active substance: Emodepside / Praziquantel) - Centralised - Yearly update - Commission Decision (2018)3405 of Tue, 29 May 2018

Europe -DG Health and Food Safety

24-5-2018

Protelos (Les Laboratoires Servier)

Protelos (Les Laboratoires Servier)

Protelos (Active substance: Strontium ranelate) - PASS - Modification - Commission Decision (2018)3270 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSR/S/13

Europe -DG Health and Food Safety

16-5-2018

Semintra (Boehringer Ingelheim Vetmedica GmbH)

Semintra (Boehringer Ingelheim Vetmedica GmbH)

Semintra (Active substance: Telmisartan) - Centralised - Variation - Commission Decision (2018)3020 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2436/X/8

Europe -DG Health and Food Safety

16-3-2018

Pending EC decision:  Semintra, telmisartan, Opinion date: 15-Mar-2018

Pending EC decision: Semintra, telmisartan, Opinion date: 15-Mar-2018

Europe - EMA - European Medicines Agency